The findings were presented at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress.
BION-1301 has demonstrated a clinically meaningful mean reduction in 24-hour proteinuria.
The candidate has been well-tolerated, with no treatment-related adverse events, SAEs, infusion-related reactions, or treatment discontinuations due to adverse events.
To date, no anti-drug antibodies have been observed in patients.
BION-1301 has durably reduced serum IgA and IgM levels and, to some extent, IgG levels.
The treatment has also resulted in significant and sustained reductions in Gd-IgA1, demonstrating depletion of the pathogenic IgA variant.
Price Action: KDNY shares are up 3.04% at $18.13 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.